Need help finding what you are looking for?
Contact Us
PUBLISHER: IMARC | PRODUCT CODE: 1820180
PUBLISHER: IMARC | PRODUCT CODE: 1820180
Vaccine Contract Manufacturing Market Report by Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), Workflow (Downstream, Upstream), Application (Human Use, Veterinary), and Region 2025-2033
PUBLISHED:
PAGES: 138 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global vaccine contract manufacturing market size reached USD 3.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.3 Billion by 2033, exhibiting a growth rate (CAGR) of 8.45% during 2025-2033.
Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols.
Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market.
Key Market Segmentation:
Breakup by Vaccine Type:
- Attenuated
- Inactivated
- Subunit-based
- Toxoid-based
- DNA-based
Breakup by Workflow:
- Downstream
- Fill and Finish Operations
- Analytical and QC Studies
- Packaging
- Upstream
- Mammalian Expression Systems
- Bacterial Expression Systems
- Yeast Expression Systems
- Baculovirus/Insect Expression Systems
- Others
Breakup by Application:
- Human Use
- Veterinary
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc.
Key Questions Answered in This Report
- 1.How big is the vaccine contract manufacturing market?
- 2.What is the future outlook of vaccine contract manufacturing market?
- 3.What are the key factors driving the vaccine contract manufacturing market?
- 4.Which are the leading companies in the global vaccine contract manufacturing market?
Product Code: SR112025A3872
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Vaccine Contract Manufacturing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Vaccine Type
- 6.1 Attenuated
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Inactivated
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Subunit-based
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Toxoid-based
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 DNA-based
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Workflow
- 7.1 Downstream
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Fill and Finish Operations
- 7.1.2.2 Analytical and QC studies
- 7.1.2.3 Packaging
- 7.1.3 Market Forecast
- 7.2 Upstream
- 7.2.1 Market Trends
- 7.2.2 Key Segments
- 7.2.2.1 Mammalian Expression Systems
- 7.2.2.2 Bacterial Expression Systems
- 7.2.2.3 Yeast Expression Systems
- 7.2.2.4 Baculovirus/Insect Expression Systems
- 7.2.2.5 Others
- 7.2.3 Market Forecast
8 Market Breakup by Application
- 8.1 Human Use
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Veterinary
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Ajinomoto Co. Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Albany Molecular Research Inc
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 SWOT Analysis
- 14.3.3 Catalent Inc
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Fujifilm Holdings Corporation
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 ICON plc
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 IDT Biologika GmbH
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Lonza Group AG
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Merck KGaA
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Pharmaceutical Product Development LLC
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 PRA Health Sciences Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.1 Ajinomoto Co. Inc.
Product Code: SR112025A3872
List of Figures
- Figure 1: Global: Vaccine Contract Manufacturing Market: Major Drivers and Challenges
- Figure 2: Global: Vaccine Contract Manufacturing Market: Sales Value (in Billion USD), 2019-2024
- Figure 3: Global: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Billion USD), 2025-2033
- Figure 4: Global: Vaccine Contract Manufacturing Market: Breakup by Vaccine Type (in %), 2024
- Figure 5: Global: Vaccine Contract Manufacturing Market: Breakup by Workflow (in %), 2024
- Figure 6: Global: Vaccine Contract Manufacturing Market: Breakup by Application (in %), 2024
- Figure 7: Global: Vaccine Contract Manufacturing Market: Breakup by Region (in %), 2024
- Figure 8: Global: Vaccine Contract Manufacturing (Attenuated) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 9: Global: Vaccine Contract Manufacturing (Attenuated) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 10: Global: Vaccine Contract Manufacturing (Inactivated) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 11: Global: Vaccine Contract Manufacturing (Inactivated) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 12: Global: Vaccine Contract Manufacturing (Subunit-based) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 13: Global: Vaccine Contract Manufacturing (Subunit-based) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 14: Global: Vaccine Contract Manufacturing (Toxoid-based) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 15: Global: Vaccine Contract Manufacturing (Toxoid-based) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 16: Global: Vaccine Contract Manufacturing (DNA-based) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 17: Global: Vaccine Contract Manufacturing (DNA-based) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 18: Global: Vaccine Contract Manufacturing (Downstream) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 19: Global: Vaccine Contract Manufacturing (Downstream) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 20: Global: Vaccine Contract Manufacturing (Upstream) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 21: Global: Vaccine Contract Manufacturing (Upstream) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 22: Global: Vaccine Contract Manufacturing (Human Use) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 23: Global: Vaccine Contract Manufacturing (Human Use) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 24: Global: Vaccine Contract Manufacturing (Veterinary) Market: Sales Value (in Million USD), 2019 & 2024
- Figure 25: Global: Vaccine Contract Manufacturing (Veterinary) Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 26: North America: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 27: North America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 28: United States: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 29: United States: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 30: Canada: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 31: Canada: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 32: Asia-Pacific: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 33: Asia-Pacific: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 34: China: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 35: China: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 36: Japan: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 37: Japan: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 38: India: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 39: India: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 40: South Korea: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 41: South Korea: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 42: Australia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 43: Australia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 44: Indonesia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 45: Indonesia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 46: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 47: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 48: Europe: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 49: Europe: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 50: Germany: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 51: Germany: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 52: France: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 53: France: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 54: United Kingdom: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 55: United Kingdom: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 56: Italy: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 57: Italy: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 58: Spain: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 59: Spain: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 60: Russia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 61: Russia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 62: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 63: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 64: Latin America: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 65: Latin America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 66: Brazil: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 67: Brazil: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 68: Mexico: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 69: Mexico: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 70: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 71: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 72: Middle East and Africa: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
- Figure 73: Middle East and Africa: Vaccine Contract Manufacturing Market: Breakup by Country (in %), 2024
- Figure 74: Middle East and Africa: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
- Figure 75: Global: Vaccine Contract Manufacturing Industry: SWOT Analysis
- Figure 76: Global: Vaccine Contract Manufacturing Industry: Value Chain Analysis
- Figure 77: Global: Vaccine Contract Manufacturing Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Vaccine Contract Manufacturing Market: Key Industry Highlights, 2024 and 2033
- Table 2: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Vaccine Type (in Million USD), 2025-2033
- Table 3: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Workflow (in Million USD), 2025-2033
- Table 4: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Application (in Million USD), 2025-2033
- Table 5: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Region (in Million USD), 2025-2033
- Table 6: Global: Vaccine Contract Manufacturing Market: Competitive Structure
- Table 7: Global: Vaccine Contract Manufacturing Market: Key Players
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.